
SI-BONE Inc (SIBN) Stock Forecast & Price Target
SI-BONE Inc (SIBN) Analyst Ratings
Bulls say
SI-BONE is a strong investment opportunity due to its record number of active physicians, continued revenue growth, and expanding product portfolio. With a proven track record of delivering above-peer growth, a capital-light business model, and strong gross margins, SI-BONE has a unique position as a leader in the minimally-invasive sacroiliac joint fusion market. While potential risks such as changes in reimbursement coverage and competitive dynamics must be monitored, SI-BONE's partnership with Smith & Nephew and upcoming product launches provide significant growth potential in the near future.
Bears say
SI-BONE is currently experiencing strong revenue growth and a favorable outlook for the future due to potential contributions from partnerships, expansion into new markets, proposed reimbursement changes, and the launch of a new product. However, there is potential for downward pressure on average selling prices and the company's profitability outlook is improving but still has room for growth. Overall, SI-BONE's revenue growth looks sustainable due to multiple products and tailwinds, but the stock may face pressure due to sector-wide multiple compression.
This aggregate rating is based on analysts' research of SI-BONE Inc and is not a guaranteed prediction by Public.com or investment advice.
SI-BONE Inc (SIBN) Analyst Forecast & Price Prediction
Start investing in SI-BONE Inc (SIBN)
Order type
Buy in
Order amount
Est. shares
0 shares